Atyr PHARMA INC (NASDAQ:ATYR) Brief Interest Update

Atyr PHARMA INC (NASDAQ:ATYR – Get Free Report ) was the target of a significant increase in short interest during the month of September. As of September 15th, there was short interest totaling 685,800 shares, up 55.5% from August 31st’s total of 440,900 shares. Currently, 0.9% of the company’s shares are short sold. Based on an average trading volume of 371,400 shares, the days-to-cover ratio is currently 1.8 days.

Changes in Analyst Ratings

Several research analysts have weighed in on ATYR shares. Jefferies Financial Group initiated coverage on shares of Atyr PHARMA in a research report on Thursday, September 5th. They set a “buy” rating and a $9.00 price target on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $16.00 target price on shares of Atyr PHARMA in a report on Wednesday, August 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research note on Thursday, August 15th.

Get the latest stock report of Atyr PHARMA

Atyr PHARMA trading up 1.2%

Shares of ATYR stock opened at $1.74 on Friday. The firm has a market cap of $131.89 million, a P/E ratio of -1.93 and a beta of 1.22. The company has a quick ratio of 7.63, a current ratio of 7.63, and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $1.87. Atyr PHARMA has a 12 month low of $1.08 and a 12 month high of $2.50.

Atyr PHARMA (NASDAQ:ATYR – Get Your Free Report ) last posted its earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01. As a group, research analysts predict that Atyr PHARMA will post -0.91 earnings per share for the current year.

Insider trading at Atyr PHARMA

In other Atyr PHARMA news, Director Paul Schimmel purchased 41,052 shares of the business’s stock in a transaction dated Monday, July 22nd. The shares were acquired at an average cost of $1.74 per share, with a total value of $71,430.48. Following the purchase, the director now owns 354,075 shares in the company, valued at approximately $616,090.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC’s website. Company insiders hold 3.70% of the company’s shares.

About Atyr PHARMA

(Get a free report)

aTyr Pharma, Inc, a biotherapeutics company, is engaged in the discovery and development of drugs based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective NRP2 modulator that is in phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for the treatment of other interstitial lung diseases (ILD), such as chronic hypersensitivity pneumonitis and ILD-related connective tissue disease.

See Also

Receive news and reviews for Atyr PHARMA daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Atyr PHARMA and related companies with MarketBeat.com’s FREE daily email newsletter.